Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development

Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation vaccine against smallpox and serves as a potent vector system for development of new candidate vaccines against infectious diseases and cancer. Historically, MVA was developed by serial tissue culture passage in prima...

Descripción completa

Detalles Bibliográficos
Autores principales: Volz, A., Sutter, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112317/
https://www.ncbi.nlm.nih.gov/pubmed/28057259
http://dx.doi.org/10.1016/bs.aivir.2016.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112317/
https://www.ncbi.nlm.nih.gov/pubmed/28057259
http://dx.doi.org/10.1016/bs.aivir.2016.07.001

Ejemplares similares